Due to increasing of life expectancy, patients with von Willebrand disease are exposed to age-related pathologies such as cancer or cardiovascular diseases. Management of thrombotic events is challenging given the inherent bleeding risk in von Willebrand disease. Few data are currently available in the literature.
The aim of the study is to describe the frequency and nature of arterial and venous thromboembolic events and atrial fibrillation in patients with von Willebrand disease in the West of France.
The investigators will perform a retrospective multicenter study conducted in the von Willebrand population of the French West. Von Willebrand adult patients followed in one of the French West medical centers participating in the study, who presented deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, acute coronary syndrome, acute limb ischemia, atrial fibrillation, arteriopathy of the lower limbs, angina will be eligible.
Von Willebrand disease
Adult
Followed-up in a reference center of West of France (Caen, Brest, Nantes, Rennes, Le Mans, Angers)
Consented to be included in BERHLINGO database
- Expression of opposition
Acquired von Willebrand syndrome
Patients under legal protection
Minor
Patients with von Willebrand disease followed in a reference center in the French West and who have consented to be included in the BERHLINGO database (Base d'Etude et de Recherche pour Les INvestigateurs en Hémostase du Grand-Ouest) with a medical history of deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, acute coronary syndrome, acute limb ischemia, angina, obliterating arteriopathy of the lower limbs or atrial fibrillation.
Cohort
Retrospective
Not listed
To describe the frequency of arterial and venous thromboembolic events and cardiac arrhythmia due to atrial fibrillation in patients with Willebrand disease in the Greater West.
Occurrence of a thromboembolic event validated by an adjudication committee
To describe the nature of arterial and venous thromboembolic events and cardiac arrhythmia due to atrial fibrillation in patients with Willebrand disease in the Greater West.
Occurrence of a thromboembolic event validated by an adjudication committee
Identify potential risk factors
identify whether certain risk factors are more prevalent in the population than others
Number of revascularisation procedures, anticoagulants and antiaggregants prescribed for these conditions
Prescription of anticoagulant and/or antiaggregant treatment
Evaluate the nature of treatments prescribed for these pathologies: revascularisation procedures, anticoagulants and antiaggregants
Revascularisation procedure (endovascular or surgical)
Evaluate the tolerance of these treatments
Occurrence of clinical haemorrhage
Click on the lead sponsor to view all of their trials.
